

R&D of a new immersive solid-phase synthesis method (TKG Therapeutics, Inc.)



| City | Year of Establishment | Founder |
|-------|-----------------------|-------------------------------------|
| Tokyo | 2022 | Akimitsu Okamoto/ Masaaki Matsui |

| Partner VC | Latest round of Fundraising | Valuation |
|-----------------------------|-----------------------------|-----------------|
| Real Tech Holdings Co.,Ltd. | Seed | JPY 300 million |

Contact Information :

tel : 050-5375-0508

e-mai: contact@tkg-na.com

Website : <https://www.tkg-na.com/en>

○ Business Plan

We are advancing the commercialization of an immersion solid-phase synthesis method known as the 'jabot-zuke' method. This synthesis method is anticipated to enable the production of nucleic acid materials that are capable of mass production, cost-effective, and have a reduced environmental impact. By commercializing this project, we aim to contribute to the expansion of the nucleic acid materials market, including nucleic acid pharmaceuticals.

○ Research Outline

We are going to create a prototype of an automated synthesizer utilizing the immersion solid-phase synthesis method, aiming to achieve the following Proof of Concept (PoC) goals: 1. Synthesis on a milligram scale using the prototype machine 2. Synthesis with less than 50% of the reaction reagent amount compared to conventional solid-phase synthesis methods 3. Synthesis of our company's proprietary new functional nucleic acids.

| Business Area/Field | Research Period | Research Grant Amount | International collaborative technology demonstration |
|---------------------|--------------------|-----------------------|--|
| Materials | STS 2023~2024FY | JPY 80 million | — |